Complete Pathologic Response of Multiple Liver Metastases and Clinical Complete Response of Rectal Cancer in a Patient with Ataxia-Telangiectasia Mutated Gene Mutations After XELOXIRI Plus Bevacizumab: A Case Report

• DOI: 10.2147/ott.s320477
• Publication Date: 2021-07-14T14:50:09Z
• Authors: Yu Cheng; Gang Wu; Simeng Zhang; Yunpeng Liu; Jinglei Qu; Xiujuan Qu
• Keywords: Regorafenib; Regimen

Doublet or triplet chemotherapy plus minus targeted drugs can achieve a high objective response rate (ORR) and are currently considered to be the backbone of conventional therapy for liver metastatic colorectal cancer (mCRC). However, current biomarkers (such as UGT1A1 DPYD) limited prediction toxicity there no effective predict response. Therefore, personalized underpinned by genomic alterations in mCRC has received increasing attention. We present case 28-year-old female rectal patient with multiple metastases (clinical risk score, CRS = 5 points). The underwent XELOXIRI bevacizumab regimen that consisted irinotecan (150 mg/m2), oxaliplatin (100 mg/m2) on day 1, capecitabine (1700 mg/m2 per from 2 15), (7.5 mg/kg) 1 (on second cycle), given every three weeks eight cycles. After multi-disciplinary team (MDT) discussion, right hemihepatectomy, partial resection segment IV cholecystectomy. Surprisingly, achieved complete pathologic (pCR) hepatic metastasis clinical (cCR) primary lesion. A paired tumor molecular profile revealed somatic mutations ataxia-telangiectasia mutated (ATM) genes may explain why such dramatic Treatment was discontinued after cycles single oral dose started follow-up program physical radiological examinations. To monitor signs recurrence, we also obtained blood samples analyze circulating DNA (ctDNA). date, remained disease-free. XELOXIRI-bevacizumab is feasible patients mCRC. Mutations ATM characterize subset better prognosis who more sensitive biological agents.